Form 4: SoftBank Affiliate Sells Vir Biotechnology Shares

SVF Endurance (Cayman) Ltd, a 10% owner and director, reported sales of Vir Biotechnology common stock totaling 330,210 shares under a Rule 10b5-1 plan.

Summary

• SVF Endurance (Cayman) Ltd, identified as a Director and 10% Owner of Vir Biotechnology, Inc. (VIR), reported the sale of 330,210 shares of common stock.
• The sales were executed in two separate transactions: 220,535 shares on October 20, 2025, and 109,675 shares on October 21, 2025.
• The shares sold on October 20, 2025, had a weighted average price of $6.1998, with individual transaction prices ranging from $6.07 to $6.2961.
• The shares sold on October 21, 2025, had a weighted average price of $6.3002, with individual transaction prices ranging from $6.12 to $6.4406.
• These sales were conducted pursuant to a pre-arranged Rule 10b5-1 trading plan, which the Reporting Person entered into on September 3, 2025.
• Following these transactions, SVF Endurance (Cayman) Ltd indirectly beneficially owns 15,010,284 shares of Vir Biotechnology common stock.
• The total value of shares sold across both transactions is approximately $2,058,301.62.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to a significant shareholder and director reducing their stake. However, the impact is mitigated by the fact that these sales were pre-planned under a Rule 10b5-1 trading plan, suggesting they are not based on new, adverse information about the company.

Negatives

• A significant shareholder and director, SVF Endurance (Cayman) Ltd, reduced its stake in Vir Biotechnology by selling 330,210 shares.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders may interpret the reduction in stake by a 10% owner and director as a potential signal of reduced confidence, although the pre-planned nature of the sales under a 10b5-1 plan lessens this concern.

Key Dates

Recommendation

The sales by a significant shareholder and director, SVF Endurance (Cayman) Ltd, typically signal a reduction in conviction or a portfolio rebalancing. While the transactions were executed under a pre-arranged Rule 10b5-1 plan, which suggests they are not based on new, negative material information, they still represent a large holder reducing exposure. This action does not provide a strong catalyst for a 'buy' recommendation, nor does it indicate a fundamental deterioration warranting a 'sell' given the pre-planned nature. Therefore, a 'hold' recommendation is appropriate, advising investors to maintain their current positions while monitoring future developments.

Keywords

Vir Biotechnology, VIR, SEC Form 4, Insider Sales, SVF Endurance, SoftBank Vision Fund, 10b5-1 plan, Beneficial Ownership